Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bergen Pursues Legislative, Managerial Remedies for PharMerica

Executive Summary

Reimbursement pressure on Bergen Brunswig's PharMerica long-term care pharmacy business is prompting the parent company to lobby for changes to Medicare's Prospective Payment System.

You may also be interested in...



McKessonHBOC Gives Ex-CEO Pulido $17.5 Mil. Severance Package

McKessonHBOC is providing former CEO Mark Pulido with a severance package worth $17.5 mil.

McKessonHBOC Gives Ex-CEO Pulido $17.5 Mil. Severance Package

McKessonHBOC is providing former CEO Mark Pulido with a severance package worth $17.5 mil.

Bristol Glucophage Strategy Lifts Stock As Sector Wilts From Medicare Redux

Bristol-Myers Squibb's diabetes portfolio was a sweetener for the Street as the stock turned in one of the few positive showings among big pharma companies during a quarter marked by increasing political rhetoric over a Medicare drug benefit.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034580

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel